{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:44:00Z","timestamp":1791499440019,"version":"4.3.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[1999,10,29]],"date-time":"1999-10-29T00:00:00Z","timestamp":941155200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[1999,11]]},"DOI":"10.1038\/sj.bjc.6690802","type":"journal-article","created":{"date-parts":[[2002,9,5]],"date-time":"2002-09-05T18:11:19Z","timestamp":1031249479000},"page":"1022-1030","source":"Crossref","is-referenced-by-count":171,"title":["Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies"],"prefix":"10.1038","volume":"81","author":[{"given":"M","family":"Brada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Judson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Beale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Reidenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Statkevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Dugan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Batra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[1999,10,29]]},"reference":[{"key":"BF6690802_CR1","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1200\/JCO.1995.13.4.910","volume":"13","author":"NM Bleehen","year":"1995","unstructured":"Bleehen, NM, Newlands, ES, Lee, SM, Thatcher, LN, Selby, P, Calvert, AH, Rustin, GJS, Brampton, M & Stevens, MFG (1995). Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 13: 910\u2013913.","journal-title":"J Clin Oncol"},{"key":"BF6690802_CR2","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1007\/s002800050691","volume":"40","author":"M Bower","year":"1997","unstructured":"Bower, M, Newlands, ES, Bleehen, NM, Brada, M, Begent, RJH, Calvert, H, Colquhoun, I, Lewis, P & Brampton, MH (1997). Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 40: 484\u2013488.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF6690802_CR3","first-page":"1241","volume":"75","author":"CS Brock","year":"1997","unstructured":"Brock, CS, Matthews, JC, Brown, G, Newlands, ES & Price, P (1997). In vivo demonstration of 11C-temozolomide uptake by human recurrent high-grade astrocytomas [abstract]. Br J Cancer 75: 1241.","journal-title":"Br J Cancer"},{"key":"BF6690802_CR4","first-page":"4884","volume":"47","author":"CV Catapano","year":"1987","unstructured":"Catapano, CV, Broggini, M, Erba, E, Ponti, M, Marianti, L, Citti, L & D\u2019Incalci, M (1987). In vitro and in vivo methazolastone-induced DNA damage and repair in L1210 leukemia sensitive and resistant to chloroethylnitrosoureas. Cancer Res 47: 4884.","journal-title":"Cancer Res"},{"key":"BF6690802_CR5","first-page":"297","volume":"35","author":"CA Carter","year":"1994","unstructured":"Carter, CA, Waud, WR & Plowman, J (1994). Responses of human melanoma, ovarian, and colon tumor xenografts in nude mice to oral temozolomide. Proc Am Assoc Cancer Res 35: 297 (abstract 1769).","journal-title":"Proc Am Assoc Cancer Res"},{"key":"BF6690802_CR6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/oxfordjournals.annonc.a059189","volume":"6","author":"S D\u2019Atri","year":"1995","unstructured":"D\u2019Atri, S, Piccioni, D, Castellano, A, Tuorto, V, Franchi, A, Lu, K, Christiansen, N, Frankel, S, Rustum, YM, Papa, G, Mandelli, F & Bonmassar, E (1995). Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: studies with blasts of leukaemic patients. Ann Oncol 6: 389\u2013393.","journal-title":"Ann Oncol"},{"key":"BF6690802_CR7","doi-asserted-by":"publisher","first-page":"9045","DOI":"10.1021\/bi00197a003","volume":"33","author":"BJ Denny","year":"1994","unstructured":"Denny, BJ, Wheelhouse, RT, Stevens, MFG, Tsang, LLH & Slack, JA (1994). NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 33: 9045\u20139051.","journal-title":"Biochemistry"},{"key":"BF6690802_CR8","first-page":"1093","volume":"3","author":"M Dhodapkar","year":"1997","unstructured":"Dhodapkar, M, Rubin, J, Reid, JM, Burch, PA, Pitot, HC, Buckner, JC, Ames, MM & Suman, VJ (1997). Phase I clinical trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res 3: 1093\u20131100.","journal-title":"Clin Cancer Res"},{"key":"BF6690802_CR9","first-page":"2853","volume":"55","author":"HS Friedman","year":"1995","unstructured":"Friedman, HS, Dolan, ME, Pegg, AE, Marcelli, S, Keir, S, Catino, JJ, Bigner, DD & Schold, SC Jr (1995). Activity of temozolomide, the treatment of central nervous system tumor xenografts. Cancer Res 55: 2853\u20132857.","journal-title":"Cancer Res"},{"key":"BF6690802_CR10","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0378-4347(97)00431-3","volume":"703","author":"KH Kim","year":"1997","unstructured":"Kim, KH, Lin, CC, Parker, D, Veals, J, Lim, J, Likhari, P, Statkevich, P, Marco, A & Nomeir, AA (1997). High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma. J Chromatogr B 703: 225\u2013233.","journal-title":"J Chromatogr B"},{"key":"BF6690802_CR11","first-page":"384a","volume":"16","author":"V Levin","year":"1997","unstructured":"Levin, V, Yung, A, Prados, M, Poisson, M, Rosenfeld, S, Brada, M, Friedman, H, Albright, R, Olson, J, Bruner, J, Yue, N & Dugan, M, Temodal Brain Group (1997). Phase II study of Temodal\u00ae (temozolomide) at first relapse in anaplastic astrocytoma (AA) patients [abstract 1370]. Proc Am Soc Clin Oncol 16: 384a.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6690802_CR12","first-page":"288","volume":"38","author":"L Liu","year":"1997","unstructured":"Liu, L, Chatterjee, S & Gerson, SL (1997). Blockade of base excision repair appears to mediate cytotoxicity to temozolomide in mismatch repair deficient tumor cells [abstract 1536]. Proc Am Assoc Cancer Res 38: 288.","journal-title":"Proc Am Assoc Cancer Res"},{"key":"BF6690802_CR13","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/bjc.1992.57","volume":"65","author":"ES Newlands","year":"1992","unstructured":"Newlands, ES, Blackledge, GRP, Slack, JA, Rustin, GJS, Smith, DB, Stuart, NSA, Quarterman, CP, Hoffman, R, Stevens, MFG, Brampton, MH & Gibson, AC (1992). Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65: 287\u2013291.","journal-title":"Br J Cancer"},{"key":"BF6690802_CR14","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1016\/S0959-8049(96)00258-4","volume":"32A","author":"ES Newlands","year":"1996","unstructured":"Newlands, ES, O\u2019Reilly, SM, Glaser, MG, Bower, M, Evans, H, Brock, C, Brampton, MH, Colquhoun, I, Lewis, P, Rice-Edwards, JM, Illingworth, RD & Richards, PG (1996). The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 32A: 2236\u20132241.","journal-title":"Eur J Cancer"},{"key":"BF6690802_CR15","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S0959-8049(05)80198-4","volume":"29A","author":"SM O\u2019Reilly","year":"1993","unstructured":"O\u2019Reilly, SM, Newlands, ES, Glaser, MG, Brampton, M, Rice-Edwards, JM, Illingworth, RD, Richards, PG, Kennard, C, Colquohoun, IR, Lewis, P & Stevens, MFG (1993). Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer 29A: 940\u2013942.","journal-title":"Eur J Cancer"},{"key":"BF6690802_CR16","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.soc.2005.04.003","volume":"14","author":"M Patel","year":"1995","unstructured":"Patel, M, McCully, C, Godwin, K & Balis, F (1995). Plasma and cerebrospinal fluid pharmacokinetics of temozolomide [abstract 1485]. Proc Am Soc Clin Oncol 14: 461.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6690802_CR17","first-page":"3793","volume":"54","author":"J Plowman","year":"1994","unstructured":"Plowman, J, Waud, WR, Koutsoukos, AD, Rubinstein, LV, Moore, TD & Grever, MR (1994). Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1 nitrosourea. Cancer Res 54: 3793\u20133799.","journal-title":"Cancer Res"},{"key":"BF6690802_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/oxfordjournals.annonc.a010490","volume":"7","author":"P Reidenberg","year":"1996","unstructured":"Reidenberg, P & Villalona, M (1996). Phase I clinical and pharmacokinetic study of temozolomide in advanced cancer patients stratified by extent of prior therapy [abstract 344]. Ann Oncol 7: 99.","journal-title":"Ann Oncol"},{"key":"BF6690802_CR19","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/0378-4347(95)00040-P","volume":"667","author":"F Shen","year":"1995","unstructured":"Shen, F, Decosterd, LA, Gander, M, Leyvraz, S, Biollaz, J & Lejeune, FJ (1995). Determination of temozolmide in human plasma and urine by high-performance liquid chromatography after solid-phase extraction. Chromatogr B 667: 291\u2013300.","journal-title":"Chromatogr B"},{"key":"BF6690802_CR20","first-page":"5846","volume":"47","author":"MFG Stevens","year":"1987","unstructured":"Stevens, MFG, Hickman, JA, Langdon, SP, Chubb, D, Vickers, L, Stone, R, Baig, G, Goddard, C, Bigson, NW, Slack, JA, Newton, C, Lunt, E, Fizames, C & Lavelle, F (1987). Anti-tumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methylimidazo (5,1-d)-1,2,3,5-tetrazin-4(3H)-one; a novel drug with potential as an alternative to dacarbazine. Cancer Res 47: 5846\u20135852.","journal-title":"Cancer Res"},{"key":"BF6690802_CR21","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/BF02994094","volume":"26","author":"LLH Tsang","year":"1990","unstructured":"Tsang, LLH, Farmer, PB, Gescher, A & Slack, JA (1990). Characterization of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity. Cancer Chemother Pharmacol 26: 429\u2013436.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF6690802_CR22","first-page":"292","volume":"37","author":"WR Waud","year":"1996","unstructured":"Waud, WR, Rubinstein, LV, Kaldandrug, S, Plowman, J & Alley, MC (1996). In vivo combination chemotherapy evaluations of topotecan with cisplatin and temozolomide [abstract 1988]. Proc Am Assoc Cancer Res 37: 292.","journal-title":"Proc Am Assoc Cancer Res"},{"key":"BF6690802_CR23","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1038\/bjc.1996.485","volume":"74","author":"SR Wedge","year":"1996","unstructured":"Wedge, SR, Porteous, JK & Newlands, ES (1996). 3-Aminobenzamide and\/or O6 benzylguanine evaluated as an adjunct to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine\u2013DNA alkyltransferase activity. Br J Cancer 74: 1030\u20131036.","journal-title":"Br J Cancer"},{"key":"BF6690802_CR24","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s002800050657","volume":"40b","author":"SR Wedge","year":"1997","unstructured":"Wedge, SR, Porteous, JK & Newlands, ES (1997a). Effect of single and multiple administration of an O6-benzylguanine\/temozolomide combination: an evaluation in a human melanoma xenograft model. Cancer Chemother Pharmacol 40b: 266\u2013272.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF6690802_CR25","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/00001813-199701000-00013","volume":"8a","author":"SR Wedge","year":"1997","unstructured":"Wedge, SR, Porteous, JK, Glaser, MG, Marcus, K & Newlands, ES (1997b). In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs 8a: 92\u201397.","journal-title":"Anticancer Drugs"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6690802.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6690802","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6690802.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:07:59Z","timestamp":1684411679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6690802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,10,29]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1999,11]]}},"alternative-id":["BF6690802"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6690802","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,10,29]]}}}